What is Skyrizi (risankizumab) and what does it target?
Skyrizi is a biologic medicine (risankizumab) that targets interleukin-23 (IL-23), a signaling protein involved in inflammatory pathways that drive several immune-mediated diseases. By binding IL-23, Skyrizi helps reduce the downstream immune activity that contributes to inflammation [1].
How does IL-23 inhibition translate into clinical effect?
IL-23 promotes inflammatory signaling in immune cells, which can lead to activation and maintenance of disease-related immune responses. Skyrizi blocks IL-23, reducing that inflammatory cascade and helping calm overactive immune signaling in affected tissues [1].
What pathways does Skyrizi affect downstream?
Because Skyrizi inhibits IL-23, it reduces IL-23–dependent immune signaling, which includes effects on T-cell–driven inflammatory responses used in the body’s defense system but misdirected in immune-mediated disease. The net effect is reduced inflammation associated with conditions where IL-23 is a key upstream driver [1].
Why is Skyrizi different from TNF inhibitors?
Many older biologics work earlier or different parts of the immune network, such as blocking tumor necrosis factor (TNF). Skyrizi’s mechanism is more specific upstream: it neutralizes IL-23, rather than blocking TNF or other single cytokines. That specificity is part of why IL-23 inhibitors like Skyrizi are often discussed as a targeted approach to IL-23-driven disease biology [1].
What conditions use Skyrizi’s IL-23 mechanism?
Skyrizi’s IL-23 mechanism is used clinically in immune-mediated conditions where IL-23 is implicated in inflammation, including plaque psoriasis and related inflammatory disorders [1].
Does Skyrizi directly block symptoms or does it work by changing immune signaling?
Skyrizi does not act as a pain reliever or symptom blocker. Its effect comes from changing immune signaling by targeting IL-23, which then reduces the inflammatory processes that produce disease manifestations over time [1].
Sources:
[1] https://www.drugpatentwatch.com/patent/risankizumab